The Rap-1 Antloncogene in Breast Cancer
Abstract
This project aims to devise strategies to antagonize the promitogenic action of Ras and thereby suppress the transforming activity of the Erb2 oncogene found in 70% of human breast adenocarcinomas. The initial strategy was based on the ability of the Rap-1 GTPase, when overexpressed to suppress the malignant phenotype of V12 Ras-transformed fibroblasts. It was anticipated that Rap-1 which shares an identical sequence corresponding to the primary Ras effector binding domain (amino acids 32-44) when overexpressed, competes with Ras for initial mitogenic effectors. In the past year, we have continued to focus on the identification and characterization of proteins that interact with Rap-i and Ras through their effector loop in GTh-dependent fashion.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1997
- Accession Number
- ADA339173
Entities
People
- Joseph Avruch
Organizations
- Massachusetts General Hospital